FUJIFILM Medical Systems USA, Inc. (Fujifilm) is a leading provider of medical image and information products and technologies for acquiring, processing, presenting, managing and storing diagnostic images. As the diagnostic imaging market continues its transformation from film-based to digitally-driven, Fujifilm's full suite of products, including conventional film, imagers, Fuji Computed Radiography (FCR®), Fuji Direct Radiography (FDR) and Synapse® Picture Archiving and Communication System (PACS), not only meet the needs of today's radiology departments, but also help customers to successfully transition to the digital future.

Headquartered in Stamford, CT, Fujifilm is a full-service diagnostic imaging company sales, service and marketing operations for the United States, and serving as the worldwide R&D software release headquarters for PACS. With its PACS products developed within Fujifilm instead of via an outside acquisition, Fujifilm and its team of experienced engineers are steadfast in their commitment to continuously innovate in PACS development and in the FCR and laser imager product lines in order to provide users with the best quality and highest productivity digital imaging systems. With nearly 40 years of expertise in the radiology market, Fujifilm has the experience, technology and vision to successfully lead its customers in the challenging healthcare environment of the 21st century.

Fujifilm is a wholly owned U.S. subsidiary of FUJIFILM Corporation, Tokyo, a nearly $25 billion high-technology company. FUJIFILM Corporation consistently ranks among the strongest companies at 217 on BusinessWeek's Global 1000 listing and at 142 on Fortune's Top 400 A-List.

With Fujifilm's new Version 5.0 software for the IIP digital x-ray technologist console, radiologists have the highest quality image display and increased diagnostic confidence at the PACS workstation.

New study finds that CT screening can reduce lung cancer mortality among smokers but won't protect them from the other adverse effects of lighting up.

Results from an evaluation of the long-term efficacy of screening fell between more positive outcomes reported by the International Early Lung Cancer Action Program (I-ELCAP) and another investigation that declared CT screening was not entirely advantageous. The latest study was published online by the RSNA June 11 and will appear in the July issue of Radiology